Enfusion (Enfusion) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Enfusion Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Enfusion is: No Data: Cannot be evaluated.

Competitive Comparison of Enfusion's Risk Assessment

For the Software - Application subindustry, Enfusion's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enfusion's Risk Assessment Distribution in the Software Industry

For the Software industry and Technology sector, Enfusion's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Enfusion's Risk Assessment falls into.

Enfusion (NYSE:ENFN) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Enfusion Risk Assessment Related Terms

Thank you for viewing the detailed overview of Enfusion's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Enfusion (Enfusion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Software » Enfusion Inc (NYSE:ENFN) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

125 South Clark Street, Suite 750, Chicago, IL, USA, 60603

Website

https://www.enfusion.com

Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.

Executives

Deirdre Somers	director	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Bradley Herring	officer: Chief Financial Officer	C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109
Oleg Movchan	director, 10 percent owner	C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603
Bronwen Bastone	officer: Chief People Officer	C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603
Stephen Malherbe	10 percent owner	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Dan Groman	officer: Chief Technology Officer	C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603
Tarek Hammoud	10 percent owner	C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603
Ftv Investment Holdings, L.p.	10 percent owner	601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108
Michael Spellacy	director	399 PARK AVENUE, NEW YORK NY 10022
Quiet Light Securities, Llc	10 percent owner	70 WEST MADISON, SUITE 1675, CHICAGO IL 60602
Steven M. Bachert	officer: Chief Revenue Officer	C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603
Lra Ventures, Llc	10 percent owner	C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Hillhouse Investment Management, Ltd.	10 percent owner	OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Roy Luo	director	394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111
Iconiq Strategic Partners V-b, L.p.	10 percent owner	394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111